Insmed announced that the Committee for Medicinal Products for Human Use (CHMP) of the EMA has adopted a positive opinion recommending approval of its DPP1 inhibitor Brinsupri (brensocatib… read more.
Teva Pharmaceutical Industries Ltd. entered into a license agreement with Prestige Biopharma, for the commercialization of Tuznue (trastuzumab), a biosimilar to Herceptin, across a majority of European markets…. read more.
Pfizer Inc and Astellas announced final overall survival (OS) results from the Phase III EMBARK study evaluating Xtandi (enzalutamide), in combination with leuprolide and as monotherapy, in men with… read more.
KalVista Pharmaceuticals, Inc. announced the acceptance of one abstract for late-breaking oral presentation and three for poster presentation at the American College of Allergy, Asthma & Immunology (ACAAI) 2025 Annual… read more.
Boehringer Ingelheim’s Jascayd (nerandomilast) has been approved by China’s National Medical Products Administration (NMPA) as an oral treatment option for idiopathic pulmonary fibrosis (IPF) in adult patients. This… read more.
Theravance Biopharma, Inc announced that it will be participating at the 36th International Symposium on the Autonomic Nervous System, organized by the American Autonomic Society (AAS), taking place November 5-8, 2025, in Clearwater… read more.
Roche announced that the FDA has approved Gazyva/Gazyvaro (obinutuzumab) for the treatment of adult patients with active lupus nephritis (LN) who are receiving standard therapy, as well as… read more.
Alexion, AstraZeneca Rare Disease, will deliver 18 presentations, including four oral presentations, from its leading rare neurology portfolio at the American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM)… read more.
Merck KGaA announced that EMD Serono, their healthcare business of Merck in the U.S. and Canada, and U.S.-President Donald J. Trump’s administration entered into an agreement to expand… read more.
Eisai Co., Ltd. and Biogen Inc. announced that Leqembi IQLIK, a subcutaneous autoinjector formulation of lecanemab (generic name), for the treatment of Alzheimer’s disease (AD) has been selected… read more.
MetaVia Inc a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, announced that an abstract highlighting data on Vanoglipel (DA-1241), a novel G-Protein-Coupled Receptor 119 (GPR119) agonist, has… read more.
AbbVie announced positive topline results from the Phase IIIb/IV head-to-head SELECT-SWITCH study evaluating the efficacy and safety of upadacitinib (Rinvoq) 15 mg, once daily, compared to adalimumab (Humira)… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
